2 children suffering from adrenoleukodystrophy saved thanks to the ELA A...(try of Research to the generosity of all...),Health

Today, ELA is even prouder of this result because this innovative approach opens up treatment perspectives for other types of leukodystrophies and most importantly to other widespread diseases (sickle cell anemia, beta-thalassemia and multiple immunodeficiencies, hemophilia, Parkinson's disease, ) which could benefit from a similar gene therapy treatment using a HIV-derived vector.

Founded in 1992 by Guy Alba, parent of a child with ALD, with the encouragement of Pr. Aubourg, chairman of the scientific committee until 2008, ELA brings together European families affected by leukodystrophies, a group of genetic diseases that destroy the myelin (nerve sheath) in the brain. Since its creation, ELA pursues the same goals: support patients, gather families and fund medical research. To accelerate the discovery of a treatment, ELA founded its own research foundation in 2005 with the support of the French Ministry of Research. The foundation's efforts and momentum permitted dedicating 30 million Euros for all kind of leukodystrophies.

Concomitantly, ELA cares for patients and brings special attention to those who may not benefit from research advances. That's why ELA commits 4.3 million Euros for the support of patients and their families needs. With the same motivations, ELA supports the development of similar organizations in Europe (Belgium, Spain, France, Italy, Luxembourg, and Switzerland).

1. extend the trial in Europe and recruit new patients including adults
2. develop a newborn screening test
3. offer the therapy to all ALD patients

Test
'/>"/>